Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
This life-threatening pediatric disease can cause sideroblastic anemia, metabolic crisis, and bone marrow failure.
Risk factors for infection and infection-related mortality were assessed in recipients of CD19 CAR T-cell therapy.
The phase 1 ALPHA2/ALPHA studies demonstrate cema-cel's safety and efficacy in relapsed LBCL.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Liso-cel outperforms standard care in second-line LBCL, showing 29.5-month EFS vs 2.4 months in TRANSFORM trial.
Infections affect 25% of LBCL patients post-CD19 CAR T-cell therapy, with risks linked to age, CRS, and poor performance.
Atara Biotherapeutics has transferred the Investigational New Drug Application for tabelecleucel.
Manali Kamdar, MD, assesses the effect on clinical practice from these label updates for CD19- and BCMA-targeting therapies.
The award recognizes achievements in the field of gene and cell therapies, cellular engineering, and related disciplines.
Hematology/oncology fellow Joseph Van Galen, MD, is investigating the mechanisms behind immune-related adverse events.
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT.
Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
Axi-cel shows durable response in high-risk LBCL frontline treatment with 80% progression-free at 3 years in ZUMA-12 trial.
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.